232 related articles for article (PubMed ID: 34557831)
1. Impact of the COVID-19 pandemic and associated non-pharmaceutical interventions on other notifiable infectious diseases in Germany: An analysis of national surveillance data during week 1-2016 - week 32-2020.
Ullrich A; Schranz M; Rexroth U; Hamouda O; Schaade L; Diercke M; Boender TS;
Lancet Reg Health Eur; 2021 Jul; 6():100103. PubMed ID: 34557831
[TBL] [Abstract][Full Text] [Related]
2. Notifiable diseases after implementation of COVID-19 public health prevention measures in Central Queensland, Australia.
Adegbija O; Walker J; Smoll N; Khan A; Graham J; Khandaker G
Commun Dis Intell (2018); 2021 Feb; 45():. PubMed ID: 33632091
[TBL] [Abstract][Full Text] [Related]
3. Epidemiology of common infectious diseases before and during the COVID-19 pandemic in Bavaria, Germany, 2016 to 2021: an analysis of routine surveillance data.
van de Berg S; Charles T; Dörre A; Katz K; Böhm S
Euro Surveill; 2023 Oct; 28(41):. PubMed ID: 37824248
[TBL] [Abstract][Full Text] [Related]
4. Persistence and Variation of the Indirect Effects of COVID-19 Restrictions on the Spectrum of Notifiable Infectious Diseases in China: Analysis of National Surveillance Among Children and Adolescents From 2018 to 2021.
Chen L; Wang L; Xing Y; Xie J; Su B; Geng M; Ren X; Zhang Y; Liu J; Ma T; Chen M; Miller JE; Dong Y; Song Y; Ma J; Sawyer S
JMIR Public Health Surveill; 2024 May; 10():e47626. PubMed ID: 38748469
[TBL] [Abstract][Full Text] [Related]
5. Changes in the incidence of invasive disease due to Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis during the COVID-19 pandemic in 26 countries and territories in the Invasive Respiratory Infection Surveillance Initiative: a prospective analysis of surveillance data.
Brueggemann AB; Jansen van Rensburg MJ; Shaw D; McCarthy ND; Jolley KA; Maiden MCJ; van der Linden MPG; Amin-Chowdhury Z; Bennett DE; Borrow R; Brandileone MC; Broughton K; Campbell R; Cao B; Casanova C; Choi EH; Chu YW; Clark SA; Claus H; Coelho J; Corcoran M; Cottrell S; Cunney RJ; Dalby T; Davies H; de Gouveia L; Deghmane AE; Demczuk W; Desmet S; Drew RJ; du Plessis M; Erlendsdottir H; Fry NK; Fuursted K; Gray SJ; Henriques-Normark B; Hale T; Hilty M; Hoffmann S; Humphreys H; Ip M; Jacobsson S; Johnston J; Kozakova J; Kristinsson KG; Krizova P; Kuch A; Ladhani SN; Lâm TT; Lebedova V; Lindholm L; Litt DJ; Martin I; Martiny D; Mattheus W; McElligott M; Meehan M; Meiring S; Mölling P; Morfeldt E; Morgan J; Mulhall RM; Muñoz-Almagro C; Murdoch DR; Murphy J; Musilek M; Mzabi A; Perez-Argüello A; Perrin M; Perry M; Redin A; Roberts R; Roberts M; Rokney A; Ron M; Scott KJ; Sheppard CL; Siira L; Skoczyńska A; Sloan M; Slotved HC; Smith AJ; Song JY; Taha MK; Toropainen M; Tsang D; Vainio A; van Sorge NM; Varon E; Vlach J; Vogel U; Vohrnova S; von Gottberg A; Zanella RC; Zhou F
Lancet Digit Health; 2021 Jun; 3(6):e360-e370. PubMed ID: 34045002
[TBL] [Abstract][Full Text] [Related]
6. Changes in Incidence of Notifiable Infectious Diseases in China Under the Prevention and Control Measures of COVID-19.
Chen B; Wang M; Huang X; Xie M; Pan L; Liu H; Liu Z; Zhou P
Front Public Health; 2021; 9():728768. PubMed ID: 34722440
[No Abstract] [Full Text] [Related]
7. The impact of the COVID-19 pandemic on other infections differs by their route of transmission: A retrospective, observational study in Japan.
Komori A; Mori H; Naito T
J Infect Chemother; 2022 Dec; 28(12):1700-1703. PubMed ID: 36064143
[TBL] [Abstract][Full Text] [Related]
8. Incidence of common infectious diseases in Japan during the COVID-19 pandemic.
Hibiya K; Iwata H; Kinjo T; Shinzato A; Tateyama M; Ueda S; Fujita J
PLoS One; 2022; 17(1):e0261332. PubMed ID: 35020724
[TBL] [Abstract][Full Text] [Related]
9. Trends and disparities in 44 national notifiable infectious diseases in China: An analysis of national surveillance data from 2010 to 2019.
Du M; Wang R; Yuan J; Lv X; Yan W; Liu Q; Qin C; Xiang N; Zhu L; Liang W; Liu M; Liu J
J Med Virol; 2023 Jan; 95(1):e28353. PubMed ID: 36443103
[TBL] [Abstract][Full Text] [Related]
10. Impact of national COVID-19 restrictions on incidence of notifiable communicable diseases in England: an interrupted time series analysis.
Nash K; Lai J; Sandhu K; Chandan JS; Shantikumar S; Ogunlayi F; Coleman PC
BMC Public Health; 2022 Dec; 22(1):2318. PubMed ID: 36510205
[TBL] [Abstract][Full Text] [Related]
11. Trends in Nationally Notifiable Infectious Diseases in Humans and Animals during COVID-19 Pandemic, South Korea.
Chang T; Cho SI; Yoo DS; Min KD
Emerg Infect Dis; 2024 Jun; 30(6):1154-1163. PubMed ID: 38781924
[TBL] [Abstract][Full Text] [Related]
12. The impact of COVID-19 on the epidemiology of non-airborne/droplet-transmitted notifiable infectious diseases in Taiwan: A descriptive study.
Hung SH; Lin WT; Wang JH; Lai CC
J Infect Public Health; 2022 Sep; 15(9):1001-1005. PubMed ID: 35981407
[TBL] [Abstract][Full Text] [Related]
13. Influence of public health and infection control interventions during the severe acute respiratory syndrome coronavirus 2 pandemic on the in-hospital epidemiology of pathogens: in hospital versus community circulating pathogens.
Dapper L; Dick A; Nonnenmacher-Winter C; Günther F
Antimicrob Resist Infect Control; 2022 Nov; 11(1):140. PubMed ID: 36369056
[TBL] [Abstract][Full Text] [Related]
14. Non-pharmaceutical interventions for COVID-19 reduced the incidence of infectious diseases: a controlled interrupted time-series study.
Zhang W; Wu Y; Wen B; Zhang Y; Wang Y; Yin W; Sun S; Wei X; Sun H; Zhang Z; Li S; Guo Y
Infect Dis Poverty; 2023 Mar; 12(1):15. PubMed ID: 36895021
[TBL] [Abstract][Full Text] [Related]
15. Effect of voluntary human mobility restrictions on vector-borne diseases during the COVID-19 pandemic in Japan: A descriptive epidemiological study using a national database (2016 to 2021).
Hibiya K; Shinzato A; Iwata H; Kinjo T; Tateyama M; Yamamoto K; Fujita J
PLoS One; 2023; 18(5):e0285107. PubMed ID: 37228070
[TBL] [Abstract][Full Text] [Related]
16. Lifting non-pharmaceutical interventions following the COVID-19 pandemic - the quiet before the storm?
Oh KB; Doherty TM; Vetter V; Bonanni P
Expert Rev Vaccines; 2022 Nov; 21(11):1541-1553. PubMed ID: 36039786
[TBL] [Abstract][Full Text] [Related]
17. The indirect impacts of nonpharmacological COVID-19 control measures on other infectious diseases in Yinchuan, Northwest China: a time series study.
Liu W; Wang R; Li Y; Zhao S; Chen Y; Zhao Y
BMC Public Health; 2023 Jun; 23(1):1089. PubMed ID: 37280569
[TBL] [Abstract][Full Text] [Related]
18. Co-benefits of nonpharmaceutical intervention against COVID-19 on infectious diseases in China: A large population-based observational study.
Xiao J; Dai J; Hu J; Liu T; Gong D; Li X; Kang M; Zhou Y; Li Y; Quan Y; He G; Zhong R; Zhu Z; Huang Q; Zhang Y; Huang J; Du Q; Li Y; Song T; Hu W; Zhong H; Ma W
Lancet Reg Health West Pac; 2021 Dec; 17():100282. PubMed ID: 34611630
[No Abstract] [Full Text] [Related]
19. [Analysis of morbidity and mortality characteristics of the notifiable diseases reported in 2013 in China].
Wang L; Zeng L; Ren X; Geng M; Li Z; Yu H
Zhonghua Liu Xing Bing Xue Za Zhi; 2015 Mar; 36(3):194-8. PubMed ID: 25975392
[TBL] [Abstract][Full Text] [Related]
20. Effects of different levels of non-pharmaceutical interventions on hand, foot and mouth disease in Guangzhou, China.
Wu K; Ma X; Liu H; Zheng J; Zhou R; Yuan Z; Huang Z; Zhong Q; Huang Y; Zhang Z; Wu X
BMC Public Health; 2022 Dec; 22(1):2398. PubMed ID: 36539790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
